A few studies have investigated the potential of autophagy-enhancing drug candidates to treat AATD-mediated liver disease such as phenothiazines, including carbamazepine and fluphenazine, with the aim of degrading mutant Z-AAT that has been retained in the ER of hepatocytes. This evidence concerns the gene SERPINA1 and liver disorder.